Clinical Trials Directory

Trials / Conditions / Recurrent Islet Cell Carcinoma

Recurrent Islet Cell Carcinoma

14 registered clinical trials studyying Recurrent Islet Cell Carcinoma.

StatusTrialSponsorPhase
CompletedRegorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
NCT02259725
University of Southern CaliforniaPhase 2
TerminatedPharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kid
NCT02273752
Emory UniversityPhase 2
WithdrawnDovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
NCT02108782
Academic and Community Cancer Research UnitedPhase 2
TerminatedEverolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With S
NCT02031536
ECOG-ACRIN Cancer Research GroupPhase 2
Active Not RecruitingTemozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
NCT01824875
ECOG-ACRIN Cancer Research GroupPhase 2
CompletedCapecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
NCT01525082
Shaheen ShaguftaPhase 2
CompletedTemozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors T
NCT01465659
Northwestern UniversityPhase 1 / Phase 2
CompletedTemsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT01155258
University of Southern CaliforniaPhase 1
CompletedSorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
NCT00131911
National Cancer Institute (NCI)Phase 2
CompletedEverolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
NCT00655655
Mayo ClinicPhase 1
TerminatedRomidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT00084461
National Cancer Institute (NCI)Phase 2
CompletedTemsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
NCT00093782
National Cancer Institute (NCI)Phase 2
CompletedGefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
NCT00075439
National Cancer Institute (NCI)Phase 2
CompletedInterleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
NCT00004074
National Cancer Institute (NCI)Phase 1